US EditionIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $55.67 Consensus PT from Analysts
Summary by ETF Daily News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $55.67 Consensus PT from Analysts
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have given a buy recommendation to the […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
